💊 GlycoMira GM-1111: A Novel Cancer Therapeutic 🏥 

By Imagine Biotech

👨‍⚕️GlycoMira x Imagine Biotech👨‍💼

In 2024, Imagine Biotech began consulting on a novel therapeutic for treatment of HNSCC in development by GlycoMira Therapeutics Inc. GM-1111, the compound developed, not only demonstrated efficacy in pre-clinical rat studies for treatment of mucositis, a common side effect of radiation therapy for HNSCC, but also shrunk tumors and protected healthy tissue minimizing the damage to surrounding areas during radiation.

After being brought on to the project, our sophisticated technologies and testing protocols yielded further data that reduced risk, both to patients and investors, and is accelerating GlycoMira’s clinical development program for GM-1111, as the company moves into their IND application. A testimonial from PhD, CEO, and Chairman of GlycoMira Dr. William Tew is below:

HNSCC: A Growing Global Concern 🌍️ 

Head and neck squamous cell carcinoma (HNSCC) is a type of cancer in the head and neck region. Each year, it accounts for nearly 890,000 new cases and 450,000 deaths worldwide, making it the seventh most common cancer overall. Its incidence continues to rise, particularly in developing regions, driven largely by lifestyle factors like tobacco (smoked or chewed), alcohol, and betel nut use.

🔎 Key Insights on HNSCC

• 🌍 Global prevalence:
  Accounts for ~4.5% of all cancer diagnoses and deaths worldwide.

• 💀 High mortality:
  Claims approximately 450,000 lives each year, indicating a significant clinical burden.

• 🔥 Risk factor synergy:
  Heavy consumption of both tobacco and alcohol elevates HNSCC risk by 40-fold.

• ⏫ Rising incidence in developing regions:
  Rapid urbanization and lifestyle changes—such as areca nut (betel quid) use—fuel the growing rates of HNSCC.

• ⚠️ Need for awareness:
  Education and prevention strategies targeting risk factors can significantly reduce the disease burden.

The Imagine Biotech Solution 🔬 

Imagine Biotech resources can call upon a wide variety of technologies to de-risk your portfolio using sophisticated pathways that have matured due to improved data resources, confounding factors, and improved model assumptions.

Our array of services range from sophisticated molecular modeling density functional methods (DFT) to the first-of-its-kind integration package of ADMET and PK predictions to academic risk.

Imagine Biotech staff have the training, expertise, and knowledge to review the proposed hypotheses (investment) in their entire journey to commercialization and select those tests/technologies to support further investment success or flag issues that arise only in the environment of review by skilled biotechnology experts.

We believe that informed investments are the cornerstone of progress. Our mission is to empower investors with the insights and tools necessary to navigate the complexities of biotech investments with confidence.